The company has increased its payouts over the past five years despite significant challenges.

The healthcare stock looks ridiculously undervalued.

Good news has been scarce for this beaten-down drugmaker.

Pfizer (PFE) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the facts that could shape the stock's performance in the near term. Shares of this ...

Pfizer (NYSE: PFE) recently experienced yet another setback. The drugmaker has been posting disappointing financial results for several years, and its latest quarterly update sent its stock price down ...

Pfizer (PFE) closed at $27.10 in the latest trading session, marking a -2.62% move from the prior day. The stock's performance was behind the S&P 500's daily gain of 0.08%. Meanwhile, the Dow ...

In recent days, analysts have repeatedly flagged ongoing competitive and pricing pressures on Pfizer’s key products, ...

Pfizer Inc PFE shares are trading lower on Tuesday after the company and its COVID-19 vaccine partner paused an updated-shot ...

Is PFE a good stock to buy now? We came across a bullish thesis on Pfizer Inc. on Investomine’s Substack. In this article, we will summarize the bulls’ thesis on PFE. Pfizer Inc.’s share was trading ...

Pfizer stock reached a 52-week high, hitting 27.99 USD, marking a significant milestone for the pharmaceutical giant. Over the past year, Pfizer has experienced a positive traject ...